E H Shao1, V Sivagnanavel2, A Dabbagh2, R Dave2, S Tempest-Roe3, F W K Tam3, S R Taylor1. 1. 1] Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK [2] Royal Surrey County Hospital NHS Foundation Trust, Egerton Road, Guildford, UK. 2. Kingston Hospital NHS Foundation Trust, Galsworthy Road, Kingston-upon-Thames, Surrey, UK. 3. Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK.
Abstract
PURPOSE: To investigate whether intravitreal ranibizumab injections administered to a child alter systemic plasma levels of total and free VEGF 165. METHODS: A 9-year-old child sustained a choroidal rupture from blunt trauma. He subsequently developed a secondary choroidal neovascular membrane, which was treated with five ranibizumab injections over a period of 8 months. Peripheral venous blood samples were taken at each visit over a period of 12 months and plasma was extracted. Plasma VEGF 165 levels were determined using enzyme-linked immunosorbent assay and were assayed both pre- and post-immunodepletion to remove complexed VEGF. RESULTS: Plasma VEGF 165 levels proved labile following intravitreal injection of ranibizumab. Levels increased by 30% above baseline following the first intravitreal ranibizumab injection, but then returned to baseline despite two subsequent injections. There was then a rebound increase of 67% in total plasma VEGF levels following a further injection, which remained above baseline for 12 weeks despite two further intravitreal ranibizumab injections. Baseline levels were re-attained 26 weeks after the final injection. CONCLUSIONS: These results suggest intravitreal ranibizumab injections can cause significant, multiphasic changes in systemic VEGF levels. This may be of particular clinical significance in children as VEGF is known to be vital in the development of major organs, in addition to its role in the maintenance of normal organ function in adults.
PURPOSE: To investigate whether intravitreal ranibizumab injections administered to a child alter systemic plasma levels of total and free VEGF 165. METHODS: A 9-year-old child sustained a choroidal rupture from blunt trauma. He subsequently developed a secondary choroidal neovascular membrane, which was treated with five ranibizumab injections over a period of 8 months. Peripheral venous blood samples were taken at each visit over a period of 12 months and plasma was extracted. Plasma VEGF 165 levels were determined using enzyme-linked immunosorbent assay and were assayed both pre- and post-immunodepletion to remove complexed VEGF. RESULTS: Plasma VEGF 165 levels proved labile following intravitreal injection of ranibizumab. Levels increased by 30% above baseline following the first intravitreal ranibizumab injection, but then returned to baseline despite two subsequent injections. There was then a rebound increase of 67% in total plasma VEGF levels following a further injection, which remained above baseline for 12 weeks despite two further intravitreal ranibizumab injections. Baseline levels were re-attained 26 weeks after the final injection. CONCLUSIONS: These results suggest intravitreal ranibizumab injections can cause significant, multiphasic changes in systemic VEGF levels. This may be of particular clinical significance in children as VEGF is known to be vital in the development of major organs, in addition to its role in the maintenance of normal organ function in adults.
Authors: Ronald Klein; Bernard Zinman; Robert Gardiner; Samy Suissa; Sandra M Donnelly; Alan R Sinaiko; Michael S Kramer; Paul Goodyer; Scot E Moss; Trudy Strand; Michael Mauer Journal: Diabetes Date: 2005-02 Impact factor: 9.461
Authors: Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Xiang-Yang Zhu; Alejandro R Chade; Martin Rodriguez-Porcel; Michael D Bentley; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2004-08-12 Impact factor: 8.311
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079
Authors: Sivashanth Gnanasekaran; Esther Bandala-Sanchez; Maria Kolic; Leonid Churilov; Sophie L Rogers; Annie K McAuley; Sukhpal S Sandhu; Salmaan Qureshi; Lyndell L Lim; Sanjeewa S Wickremasinghe Journal: Mol Vis Date: 2020-04-01 Impact factor: 2.367